HEPTA
Medical is developing a unique minimally invasive non surgical treatment
modality for early lung cancer, allowing for a real time, targeted and
adapted ablation of the lesions.
Lung cancer is the leading cause of cancer death around the world with 2.1
million patients diagnosed each year, with lung cancer related mortality largely unchanged for the past 40
years (1). Recent results from a major trial (2) demonstrated the positive impact of
lung screening programs on mortality, dramatically impacting the
pulmonology practice. Since then, technological advances have been oriented
towards the development of modalities combining navigation, access,
diagnosis and on the spot treatment. As of today, surgical resection remains the Standard of care, but 75% patients
are not surgical candidates.
HEPTA Medical is developing a sensor, embedded into a bronchoscopic or percutaneous ablation catheter, which provides temperature-based feedback. This enables real-time dosing to precisely target and
ablate pulmonary nodules, the precursor of lung cancer, without the need for
surgery or radiation.
HEPTA Medical has finalized its prototype design and completed its pre-clinical validation. The company is currently looking for a strategic partner to get into the clinic.
(1) Ten year survey of lung cancer treatment and
survival in hospitals in the United States: a national cancer database
report. Cancer1999;86:1867?"76.
(2) N Engl J Med 2011; 365:395-409